Page 9 - Roche Hemlibra Non-inhibitors - Product Monograph

74% 74% of which (62,241,855 AED) is spent on drug acquisition costs

26% 26% of which (21,580,171 AED) is spent on non-drug acquisition cost

More than 21.5 million AED are spent on the management of bleeds, despite the high rate of adequate
prophylaxis with factor replacement. Prophylaxis rate is estimated to be 96%.

In 5 years’ time horizon, more than 108 million AED are spent on the management of bleeds, that are
not captured in the drug acquisition cost.
In 5 years’ time horizon, each patient costs around 1.6 million AED which are not related to the
prophylaxis drug cost and are spent on the management of bleeds and surgeries.

Non−drug-related direct costs should not be underestimated. A substantial proportion of hemophilia A
patients have at least one visit to the emergency department (approximately 30%) or undergo at least
one hospitalization (approximately 15% to 20%) per year (Guh et al. 2012a; Zhou et al. 2015).

Reasons behind an increase in the non−drug-related costs:

Inadequate Prophylaxis usage of
treatment on factor factors does not protect
replacement patients from bleeds,
or from developing
target joints

Increasing Additional
severity of the disease-related
disease complications

E.g., significantly higher costs in patients with target joints than for patients without target joints

HEMLIBRA Monograph-Non-inhibitors | 07
®